MUC5B genetic variants and shorter telomeres — or chromosome endings — are risk factors associated with greater lung damage and poorer survival in Chinese patients with idiopathic pulmonary fibrosis (IPF), a study has revealed. The study, “The relationship between MUC5B promoter, TERT polymorphisms and telomere…
MUC5B Genetic Variants, Short Telomeres Linked to Greater Lung Damage, Poorer Survival in Chinese Patients, Study Shows
A genetic variant at the IFNL3 gene is linked to raised levels of IFN-lambda 3 in the blood and is associated with the presence of pulmonary fibrosis in patients with systemic sclerosis, but it does not represent a risk factor for worsening of skin fibrosis in these patients, a…
Managing a chronic illness is not for the faint of heart. Learning to live with idiopathic pulmonary fibrosis (IPF) is the hardest thing I’ve ever done. I applaud my colleagues at Bionews Services and the friends I’ve made around the world who share their stores and advocate for others.
People with non-small cell lung cancer (NSCLC) who also have pulmonary fibrosis and emphysema are at a greater risk of acute flares following cancer treatment that includes chemotherapy, surgery, or radiotherapy, a study from South Korea reports. The study “Combined pulmonary fibrosis and emphysema and idiopathic pulmonary fibrosis in…
It’s been seven months since my mom, Holly, had a double-lung transplant. She and the miracle organs that have been stitched within her are going strong. But their relationship hasn’t been perfect. My mom’s body and her new lungs each brought their own baggage to the relationship.
First IPF Patient Dosed in Phase 1 Trial of Potential Oral Anti-fibrotic Therapy, Indalo Announces
Indalo Therapeutics announced that dosing has begun in the first patient enrolled in its Phase 1 trial assessing the safety, tolerability, and properties of IDL-2965, the company’s lead candidate to treat fibrotic diseases including idiopathic pulmonary fibrosis (IPF). IDL-2965 is an oral, selective antagonist of three types…
After my single-lung transplant in December 2015, I was invited to participate in a panel of idiopathic pulmonary fibrosis (IPF) and lung transplant patients who had previously taken the anti-fibrotic medications Ofev (nintedanib) or Esbriet (pirfenidone). My pulmonologist had asked me to take part in a…
For the third day in a row, I’ve been feeling angry with my body, particularly my lungs. I’ve been experiencing severe breathlessness. While I don’t have signs of a viral or bacterial infection, I’m struggling to hold a conversation because of my need to pause frequently. This level of…
Data Support Envisia Classifier Helping to More Quickly and Accurately Diagnose IPF, Veracyte Says
Veracyte announced new data further supporting its Envisia Genomic Classifier as a useful tool in helping doctors to diagnosis idiopathic pulmonary fibrosis (IPF) with greater confidence and without the need for surgery to biopsy lung…
Healthy and idiopathic pulmonary fibrosis (IPF) lung cells respond differently to transforming growth factor-beta 1 (TGF-beta 1) — a key mediator of fibrosis — both in terms of gene activity and DNA methylation, likely due to the fibrotic environment that IPF cells are exposed to in the lungs,…
Your PF Community
Recent Posts
- IPF drug Esbriet lowers risk of irregular heartbeats by nearly 90%, per study February 11, 2026
- Every patient’s journey with IPF is part of a unique mystery February 10, 2026
- New IPF therapy modulates genes tied to inflammation and scarring February 4, 2026
- My journey with PF and transplant means lifelong medical surveillance February 3, 2026
- Learning about the link between autoimmune disease and PF January 29, 2026
